Effects of Subcutaneous Repository Corticotropin Gel Injection on Regulatory T Cell Population in Noninfectious Retinal Vasculitis. (16th March 2023)

• Record Type: Journal Article
• Authors: Anesi, Stephen D.; Chang, Peter Y.; Maleki, Arash; Manhapra, Ambika; Look-Why, Sydney; Asgari, Soheila; Walsh, Marisa; Drenen, Kayla; Foster, C. Stephen
• Is Part Of: Ocular immunology and inflammation. Volume 31:Number 3(2023)
• Page Start: 556
• Page End: 565
• Publication Date: 2023-03-16
• Subjects: Acthar -- CD4+ -- CD25+ -- FoxP3+ -- regulatory T cell -- repository corticotropin injection (RCI) -- retinal vasculitis -- Treg -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2022.2042323
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Aim: To evaluate the effect of repository corticotropin injection (RCI) on regulatory T cell population in patients with noninfectious retinal vasculitis. Patients and Methods: Patients with active noninfectious retinal vasculitis were included in a prospective nonrandomized open-label study. Results: Eighteen patients (33 eyes) were included in the study. Eleven (61.1%) patients [20 (60.6%) eyes] and 7 (38.9%) patients [13 (33.3%) eyes] were in the responsive and non-responsive groups, respectively. We did not find any statistically significant difference within the PPP-R group, within the PPP-NR group, or between these two groups in regard to regulatory T cell population. No significant systemic or ocular complications were found. Conclusion: RCI may be a complementary treatment in patients with non-infectious retinal vasculitis with or without uveitis. This study did not demonstrate an increase in regulatory T cell population in patients with noninfectious retinal vasculitis.